Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Therapeutic targeting of Syk in autoimmune diabetes.

Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovsky A, Clynes R.

J Immunol. 2010 Aug 1;185(3):1532-43. doi: 10.4049/jimmunol.1000983. Erratum in: J Immunol. 2011 Aug 1;187(3):1516.

2.

A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation.

Sedlik C, Orbach D, Veron P, Schweighoffer E, Colucci F, Gamberale R, Ioan-Facsinay A, Verbeek S, Ricciardi-Castagnoli P, Bonnerot C, Tybulewicz VL, Di Santo J, Amigorena S.

J Immunol. 2003 Jan 15;170(2):846-52.

3.

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.

Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG.

Blood. 2010 Dec 2;116(23):4894-905. doi: 10.1182/blood-2010-03-275180.

4.

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.

Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T.

J Dermatol Sci. 2014 Jun;74(3):214-21. doi: 10.1016/j.jdermsci.2014.02.008.

PMID:
24679982
5.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL.

Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.

6.

The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.

Platt AM, Benson RA, McQueenie R, Butcher JP, Braddock M, Brewer JM, McInnes IB, Garside P.

Rheumatology (Oxford). 2015 Jan;54(1):169-77. doi: 10.1093/rheumatology/keu273.

7.

Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.

Leonhardt F, Zirlik K, Buchner M, Prinz G, Hechinger AK, Gerlach UV, Fisch P, Schmitt-Gräff A, Reichardt W, Zeiser R.

Leukemia. 2012 Jul;26(7):1617-29. doi: 10.1038/leu.2012.10.

PMID:
22301676
8.

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E.

Clin Immunol. 2007 Sep;124(3):244-57.

PMID:
17537677
9.

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI.

Arthritis Rheum. 2008 May;58(5):1433-44. doi: 10.1002/art.23428.

10.

A distinct role of CD4+ Th17- and Th17-stimulated CD8+ CTL in the pathogenesis of type 1 diabetes and experimental autoimmune encephalomyelitis.

Ankathatti Munegowda M, Deng Y, Chibbar R, Xu Q, Freywald A, Mulligan SJ, van Drunen Littel-van den Hurk S, Sun D, Xiong S, Xiang J.

J Clin Immunol. 2011 Oct;31(5):811-26. doi: 10.1007/s10875-011-9549-z.

11.

Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses.

Desai DD, Harbers SO, Flores M, Colonna L, Downie MP, Bergtold A, Jung S, Clynes R.

J Immunol. 2007 May 15;178(10):6217-26.

12.

Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.

Miller AL, Zhang C, Shokat KM, Lowell CA.

J Immunol. 2009 Jan 15;182(2):988-98.

13.

A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages.

Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL.

J Exp Med. 1997 Oct 6;186(7):1027-39.

14.

B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells.

Zhang AH, Li X, Onabajo OO, Su Y, Skupsky J, Thomas JW, Scott DW.

J Autoimmun. 2010 Sep;35(2):107-13. doi: 10.1016/j.jaut.2010.05.002. Erratum in: J Autoimmun. 2011 Mar;36(2):171.

15.

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, Potter TA, Refaeli Y.

Blood. 2009 Mar 12;113(11):2508-16. doi: 10.1182/blood-2008-05-158618.

16.

Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.

Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.

Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256.

PMID:
18855194
17.

Bruton's Tyrosine Kinase Synergizes with Notch2 To Govern Marginal Zone B Cells in Nonobese Diabetic Mice.

Case JB, Bonami RH, Nyhoff LE, Steinberg HE, Sullivan AM, Kendall PL.

J Immunol. 2015 Jul 1;195(1):61-70. doi: 10.4049/jimmunol.1400803.

18.
19.

Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis.

Ozaki N, Suzuki S, Ishida M, Harada Y, Tanaka K, Sato Y, Kono T, Kubo M, Kitamura D, Encinas J, Hara H, Yoshida H.

Int Immunol. 2012 Sep;24(9):539-50. doi: 10.1093/intimm/dxs078.

20.
Items per page

Supplemental Content

Support Center